PT  - JOURNAL ARTICLE
AU  - Aneza Roussou
AU  - Andriana Papaioannou
AU  - Effrosyni Manali
AU  - Aris Spathis
AU  - Nikoletta Pianou
AU  - Alexandros Georgakopoulos
AU  - John Tomos
AU  - Anna Karakatsani
AU  - Kostantinos Kostikas
AU  - Sofia Chatziioannou
AU  - Petros Karakitsos
AU  - Spyros Papiris
TI  - Serum levels of sestrin 2 in patients with sarcoidosis
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P3797
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P3797.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P3797.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - Introduction:Oxidative stress is involved in pathogenesis of Sarcoidosis. Sestrins are proteins with antioxidative capacity that accumulate in cells exposed to oxidative stress. The aim of our study was to test whether serum sestrin 2 (Ses2) levels in patients with sarcoidosis are related to disease extent, to the involvement of specific organs and to treatment with corticosteroidsMethods:Serum samples were collected from consecutive patients with sarcoidosis. Patients underwent pulmonary function tests, chest X-ray, HRCT and Positron Emission Tomography (PET). Patients with involvement of 3 or more organs were considered to have extended disease. Serum Ses2 levels were measured with ELISAResults:35 patients (22 female) (mean age 54.0±14.4 years) were included in the study. Serum Se2 levels were higher in patients with limited disease compared to patients with extended disease [median(IQR) 3.19(1.61, 7.72) vs 0.89(0.68, 2.66)ng/mL, respectively p=0.009. Steroid naive patients with limited disease had higher serum Ses2 levels compared to those with extended disease [3.27(1.62, 18.19) vs 0.94(0.81, 2.17) respectively, p=0.024]. However, serum Ses2 levels were not related to disease extend in patients receiving corticosteroids [3.39(1.14, 6.16) vs 0.79(0.53, 5.09) for limited and extended disease respectively p=0.159]. Serum Ses2 levels were higher in patients with no node involvement compared to patients with any node involvement [4.96(1.63, 18.19) vs 1.88(0.88, 3.19) respectively p=0.036]Conclusion:Serum Ses2 levels are lower in patients with extended sarcoidosis and those with node involvement. Corticosteroids seem to affect serum Ses2 levels. The possible antioxidative role of Ses2 in sarcoidosis has to be further evaluated.